Abstract

PURPOSEA large proportion of patients with cancer suffer from breakthrough cancer pain (BTcP). Several unmet clinical needs concerning BTcP treatment, such as optimal opioid dosages, are being investigated. In this analysis the hypothesis, we explore with an unsupervised learning algorithm whether distinct subtypes of BTcP exist and whether they can provide new insights into clinical practice.METHODSPartitioning around a k-medoids algorithm on a large data set of patients with BTcP, previously collected by the Italian Oncologic Pain Survey group, was used to identify possible subgroups of BTcP. Resulting clusters were analyzed in terms of BTcP therapy satisfaction, clinical features, and use of basal pain and rapid-onset opioids. Opioid dosages were converted to a unique scale and the BTcP opioids-to-basal pain opioids ratio was calculated for each patient. We used polynomial logistic regression to catch nonlinear relationships between therapy satisfaction and opioid use.RESULTSOur algorithm identified 12 distinct BTcP clusters. Optimal BTcP opioids-to-basal pain opioids ratios differed across the clusters, ranging from 15% to 50%. The majority of clusters were linked to a peculiar association of certain drugs with therapy satisfaction or dissatisfaction. A free online tool was created for new patients’ cluster computation to validate these clusters in future studies and provide handy indications for personalized BTcP therapy.CONCLUSIONThis work proposes a classification for BTcP and identifies subgroups of patients with unique efficacy of different pain medications. This work supports the theory that the optimal dose of BTcP opioids depends on the dose of basal opioids and identifies novel values that are possibly useful for future trials. These results will allow us to target BTcP therapy on the basis of patient characteristics and to define a precision medicine strategy also for supportive care.

Highlights

  • Breakthrough cancer pain (BTcP) is a common event that affects a considerable proportion of patients with cancer.[1]

  • This paper demonstrates a novel approach for the investigation of BTcP

  • Our findings identified 12 subtypes of BTcP with peculiar response to drugs and clinical presentation

Read more

Summary

Introduction

Breakthrough cancer pain (BTcP) is a common event that affects a considerable proportion of patients with cancer.[1]. According to the Italian Oncologic Pain Survey (IOPS) study group,[4] BTcP should be defined “as a relevant change in pain intensity of severe intensity in patients who receive an effective treatment with opioids.”4(p963) despite this unique definition, BTcP encloses a wide range of manifestations that differ, among other features, in intensity, duration, frequency, and triggering events. It is difficult to achieve an acceptable degree of relief because patients with cancer have complex pain syndromes. These patients often require more intense therapeutic protocols and, more time may be required to achieve adequate pain control.[5]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call